Scientists have identified factors associated with an increased likelihood of breast cancer being diagnosed in the interval between routine mammograms, which could ultimately help make breast cancer ...

The Centre for In Vivo Modelling is a newly established research centre within the Division of Cancer Biology at the ICR. Our scientists and clinical researchers use state-of-the-art in vivo models to ...

A new atlas mapping how more than 10,000 tumours across 28 cancer types are predicted to use nutrients has been created, revealing potential weaknesses that could be exploited to develop new cancer ...

The division is focused on identifying both the genetic and environmental causes of breast cancer, so we can improve diagnosis, assess prognosis and likely response to treatment more accurately, and ...

The latest major breakthrough in cancer is a drug called capivasertib, which has shown ‘remarkable’ results against advanced breast cancer in its first phase III trial. Results released at the ...

A spit test, where a sample can be collected at home, is more accurate at identifying future risk of prostate cancer for some men than the current standard PSA blood test, a new study reports. Results ...

As we enter 2026, scientists at The Institute of Cancer Research, London, share the developments expected this year that could soon change how cancer is treated – from technologies designed to deliver ...

Scientists have discovered a key protein that could be targeted with a drug to treat the most common and aggressive form of pancreatic cancer. The findings, published in Nature, show that blocking the ...

Two decades ago, a pivotal exchange between two scientists sparked a scientific and medical revolution. Professor Alan Ashworth, then Director of the Breast Cancer Now Toby Robins Research Centre at ...

The Institute of Cancer Research, London, is the joint recipient of a major new Medical Research Council (MRC) grant to advance how sensitive medical imaging data can be used for research. This award ...

A new immunotherapy drug has shown promise for safely treating prostate cancer, a phase I trial reports. Almost half of the patients in the trial that could be evaluated saw their tumour shrink after ...